StockData
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc. (TNYA) stock

TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$0.31−0.02 (-4.93%)

Close on Nov 18, 2026Market cap $68.82MP/E –Yield –

Tenaya Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Tenaya Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$52.33M. For fiscal 2025 it was -$68.26M. The highest annual figure on record is -$35.45M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$68.26M–
FY2024Dec 31, 2024-$90.50M–
FY2023Dec 31, 2023-$102.07M–
FY2022Dec 31, 2022-$104.42M–
FY2021Dec 31, 2021-$60.81M–
FY2020Dec 31, 2020-$35.45M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.55M–
Q1 FY2026Mar 31, 2026-$19.23M–
Q4 FY2025Dec 31, 2025-$13.94M–
Q3 FY2025Sep 30, 2025-$15.60M–
Q2 FY2025Jun 30, 2025-$15.61M–
Q1 FY2025Mar 31, 2025-$23.11M–
Q4 FY2024Dec 31, 2024-$18.39M–
Q3 FY2024Sep 30, 2024-$19.84M–
Q2 FY2024Jun 30, 2024-$23.62M–
Q1 FY2024Mar 31, 2024-$28.66M–
Q4 FY2023Dec 31, 2023-$21.92M–
Q3 FY2023Sep 30, 2023-$23.64M–
Q2 FY2023Jun 30, 2023-$26.22M–
Q1 FY2023Mar 31, 2023-$30.29M–
Q4 FY2022Dec 31, 2022-$22.68M–
Q3 FY2022Sep 30, 2022-$27.56M–
Q2 FY2022Jun 30, 2022-$25.43M–
Q1 FY2022Mar 31, 2022-$28.76M–
Q4 FY2021Dec 31, 2021-$16.35M–
Q3 FY2021Sep 30, 2021-$16.66M–
Q2 FY2021Jun 30, 2021-$12.02M–
Q1 FY2021Mar 31, 2021-$15.79M–
Q4 FY2020Dec 31, 2020-$10.40M–
Q3 FY2020Sep 30, 2020-$9.53M–

More Tenaya Therapeutics figures

See a number that looks wrong?